5 Minutes Read
US FDA observations normal & routine, says Galaxy Surfactants
KV Prasad Jun 13, 2022, 06:35 AM IST (Published)
Listen to the Article (6 Minutes)
Summary
The US food and drug administration (USFDA) has issued 4 observations for M3 plant and 9 observations for N46 plant in Tarapur of Galaxy Surfactants. In an interview with CNBC-TV18, U Shekhar, Founder and Managing Director of the company spoke about the latest happenings in his company and sector. “Though we have been manufacturing and …
Continue reading “US FDA observations normal & routine, says Galaxy Surfactants”
The US food and drug administration (USFDA) has issued 4 observations for M3 plant and 9 observations for N46 plant in Tarapur of Galaxy Surfactants.
In an interview with CNBC-TV18, U Shekhar, Founder and Managing Director of the company spoke about the latest happenings in his company and sector.
“Though we have been manufacturing and selling these products in the US for the last so many years, this is for the first time that US FDA has come to our premises for an audit. These observations are normal and routine in nature. These do not preclude us from selling our products in the US market at all,” he said.
“We will continue to be selling in US markets, these observations don’t prohibit us or preclude us from selling it in the US market. These are procedural in nature,” he added.
Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout
3 Mins Read
Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter
Daily Newsletter
